DGAP-News
337
0 Kommentare
MeVis Q2 2015: Revenues benefit from strong US dollar
337 
0 KommentareDGAP-News: MeVis Medical Solutions AG / Key word(s): Half Year
Results/Interim Report
MeVis Q2 2015: Revenues benefit from strong US dollar
11.08.2015 / 15:50
---------------------------------------------------------------------
Significant increase in revenues from strong US dollar, at the same time
slightly weaker results
- Sales in the second quarter increased by 15 % to EUR 3.7 m due to the
strong US dollar (prev. year: EUR 3.2 m)
- Earnings before interest and taxes (EBIT) decreased to EUR 1.6 m (prev.
year EUR 1.8 m), EBIT margin of 23 %
- Net profit declined to EUR 1.3 m (prev. year EUR 1.7 m)
- Liquidity of EUR 21.6 m as at June 30, 2015 (Dec. 31, 2014: EUR 17.5 m)
Bremen, August 11, 2015 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4],
a leading provider of medical imaging software, today announced its results
for the first half of 2015.
Sales in the second quarter of 2015 came to EUR 3,730 k, 15 % higher than
in the second quarter of 2014 (EUR 3,234 k) and surpassing the first
quarter of 2015 (EUR 3,408 k). At EUR 7,138 k, sales in the first half of
the year increased considerably year on year (prev. year: EUR 6,062 k). The
growth in sales is entirely attributable to the US dollar exchange rate,
which contributed EUR 1,145 k to sales growth in the half year. Revenues
generated from licensing business increased by 8 % to TEUR 3,326, revenues
from maintenance business increased by 11 % to TEUR 3,080, accounting for
43 % of total sales. Sales in the Digital Mammography segment increased by
19 % to EUR 5,637 k (prev. year: EUR 4,738 k) and sales in the Other
Diagnostics segment increased by 13 % to EUR 1,501 k (prev. year: EUR 1,324
k).
Staff costs increased in the second quarter according to plan by 2 % to EUR
1,798 k (prev. year: EUR 1,755 k), resulting in an identical increase of 2
% (from EUR 3,567 k to EUR 3,635 k) for the first half of the year. Other
operating expenses fell in the second quarter by 19 % to EUR 453 k (prev.
year: EUR 559 k), but increased by 3 % cumulative in the first half of
2015.
The capitalization of development expenses was ceased in the fourth quarter
of 2014 (prev. year: EUR 841 k).
Due to increased sales and despite the cessation of the capitalization of
development expenses, MeVis sees a slight increase of the EBITDA (earnings
before interest, taxes, depreciation and amortization) by 2 %, from EUR
2,605 k to EUR 2,667 k.
After depreciation and amortization of EUR 1,040 k (up 27 % year on year),
this results in an EBIT (earnings before interest and taxes) of EUR 1,627 k
(with 9 % well below the previous year's figure of EUR 1,789),
corresponding to an EBIT margin of 23 % (prev. year: 30 %).
The net financial result improved by EUR 271 k to EUR 428 k year on year.
Mainly the development of the US$ exchange rate and the improvement of the
MeVis BreastCare have contributed to this. Income tax expenses increased by
EUR 568 k to EUR 787 k, which results mostly from deferred taxes.
Net profit fell by EUR 459 k to EUR 1,268 k, which is equivalent to
undiluted earnings per share of EUR 0.72 (prev. year: 1.00).
Cash and cash equivalents increased by EUR 4,052 k to EUR 21,563 k as of
June 30, 2015 compared to the end of 2014. This includes EUR 1,707 k from
the sale of treasury shares to the VMS Deutschland Holdings GmbH in April
2015.
The Company's financial reports can be downloaded from the following
website:
http://www.mevis.de/en/investor-relations/financial-reports/
---------------------------------------------------------------------
11.08.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
385663 11.08.2015
Significant increase in revenues from strong US dollar, at the same time
slightly weaker results
- Sales in the second quarter increased by 15 % to EUR 3.7 m due to the
strong US dollar (prev. year: EUR 3.2 m)
- Earnings before interest and taxes (EBIT) decreased to EUR 1.6 m (prev.
year EUR 1.8 m), EBIT margin of 23 %
- Net profit declined to EUR 1.3 m (prev. year EUR 1.7 m)
- Liquidity of EUR 21.6 m as at June 30, 2015 (Dec. 31, 2014: EUR 17.5 m)
Bremen, August 11, 2015 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4],
a leading provider of medical imaging software, today announced its results
for the first half of 2015.
Sales in the second quarter of 2015 came to EUR 3,730 k, 15 % higher than
in the second quarter of 2014 (EUR 3,234 k) and surpassing the first
quarter of 2015 (EUR 3,408 k). At EUR 7,138 k, sales in the first half of
the year increased considerably year on year (prev. year: EUR 6,062 k). The
growth in sales is entirely attributable to the US dollar exchange rate,
which contributed EUR 1,145 k to sales growth in the half year. Revenues
generated from licensing business increased by 8 % to TEUR 3,326, revenues
from maintenance business increased by 11 % to TEUR 3,080, accounting for
43 % of total sales. Sales in the Digital Mammography segment increased by
19 % to EUR 5,637 k (prev. year: EUR 4,738 k) and sales in the Other
Diagnostics segment increased by 13 % to EUR 1,501 k (prev. year: EUR 1,324
k).
Staff costs increased in the second quarter according to plan by 2 % to EUR
1,798 k (prev. year: EUR 1,755 k), resulting in an identical increase of 2
% (from EUR 3,567 k to EUR 3,635 k) for the first half of the year. Other
operating expenses fell in the second quarter by 19 % to EUR 453 k (prev.
year: EUR 559 k), but increased by 3 % cumulative in the first half of
2015.
The capitalization of development expenses was ceased in the fourth quarter
of 2014 (prev. year: EUR 841 k).
Due to increased sales and despite the cessation of the capitalization of
development expenses, MeVis sees a slight increase of the EBITDA (earnings
before interest, taxes, depreciation and amortization) by 2 %, from EUR
2,605 k to EUR 2,667 k.
After depreciation and amortization of EUR 1,040 k (up 27 % year on year),
this results in an EBIT (earnings before interest and taxes) of EUR 1,627 k
(with 9 % well below the previous year's figure of EUR 1,789),
corresponding to an EBIT margin of 23 % (prev. year: 30 %).
The net financial result improved by EUR 271 k to EUR 428 k year on year.
Mainly the development of the US$ exchange rate and the improvement of the
MeVis BreastCare have contributed to this. Income tax expenses increased by
EUR 568 k to EUR 787 k, which results mostly from deferred taxes.
Net profit fell by EUR 459 k to EUR 1,268 k, which is equivalent to
undiluted earnings per share of EUR 0.72 (prev. year: 1.00).
Cash and cash equivalents increased by EUR 4,052 k to EUR 21,563 k as of
June 30, 2015 compared to the end of 2014. This includes EUR 1,707 k from
the sale of treasury shares to the VMS Deutschland Holdings GmbH in April
2015.
The Company's financial reports can be downloaded from the following
website:
http://www.mevis.de/en/investor-relations/financial-reports/
---------------------------------------------------------------------
11.08.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
385663 11.08.2015
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Auch bei Lesern beliebt
